Hey guys,

I wanted to get your opinion on Cellectar Biosciences ($CLRB (+0%) ). The share has completely collapsed in the last few months - over 80% loss since December. But is there still potential here?

What is Cellectar doing?

Cellectar is a biotech company specializing in targeted cancer therapies. cancer therapies with radioactive agents. Its focus is on phospholipid drug conjugates (PDCs), which are used to transport drugs directly to cancer cells.

The most important drug is Iopofosine I-131a radiotherapy for the treatment of rare blood cancers. The drug uses an innovative mechanism: it is taken up directly by cancer cells while healthy tissue is spared.

What happened?

- Phase 2 trial in Waldenström's disease (WM) successfully completed.

- FDA requires an additional confirmatory study before approval is possible.

- Share subsequently plummets by over 80% because the approval process is delayed.

Financial situation: ✅

- USD 34 million in cash and cash equivalents (as at September 2024) 💸

- Debt-free 🚫

- Current market capitalization: approx. USD 14.65 million 💰

- Current share price: approx. USD 0.31 📉

Opportunities & risks:

✅ Innovative drug: If Iopofosine I-131 achieves approval, it could be a significant breakthrough for rare blood cancers.

✅ Targeted cancer therapy: The PDC approach could be used in several indications in the long term.

✅ Solid financial position: Debt-free and with sufficient capital for short-term studies.

⚠ Delay by FDA: The additional study costs time and money, and it is unclear when approval will be realistic.

⚠ High uncertainty: After the dramatic fall in the share price, investor confidence has been shaken.

⚠ Possible need for capital: If the studies take longer, Cellectar could need fresh money.

What do you think?

Is this a turnaround opportunity or more of a money pit? Would you get in at USD 0.31 or would you rather keep your hands off it? Looking forward to your opinions!

🔗 https://www.sharedeals.de/atos-aktie-verkaufen-vor-reverse-split/